Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Dr Teresa Amaral Highlights Value of ESMO-MCBS for Access to Cancer Medicines at EU Conference on HTA

22 Nov 2023

Teresa Amaral - member of the ESMO Council and the ESMO-MCBS Working Group - presented the ESMO-Magnitude of Clinical Benefit Scale, and the role of this tool in supporting decision-making on the value of new cancer medicines, as part of a stakeholder panel at the conference From Theory to Practice: Implementing the EU Health Technology Assessment Regulation held on 22 November 2023 in Seville, Spain. “The integration of the ESMO-MCBS within the new processes can further help deliver the HTA Regulation vision: to improve patient access to new cancer medicines,” says Dr Amaral.

The European Union’s (EU) Health Technology Assessment (HTA) Regulation, set to enter into application in January 2025, will introduce new EU-wide procedures for assessing the clinical value of new health technologies, including medicines for treating cancer. The conference held in Seville is the third in a series of seven regional stakeholder conferences being held to inform stakeholders about the implementation of the HTA Regulation, with the Seville meeting focussing on stakeholders from Spain, Italy, Malta and Portugal.

When speaking at the conference, Dr Amaral presented the ESMO-MCBS and underlined its role in facilitating improved decision-making regarding the value of anti-cancer therapies, with the goal to promote the accessibility of these therapies and reduce iniquity of access to high value cancer treatments. She explained that, if used as a supportive tool for the new joint HTA processes, the ESMO-MCBS holds great potential to help improve access to innovative cancer therapies, to the benefit of patients with cancer.

Dr Amaral concluded by emphasising ESMO’s willingness to support the implementation of the HTA Regulation across the EU: “As a European society representing 34,000 oncology professionals, ESMO is very supportive of the new HTA processes, and also about the fact that joint assessments will start with medicines for treating cancer. ESMO is in that regard happy to become involved as a consultative partner”.


This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.